BMO Capital Reiterates Gilead Sciences (GILD) at Market Perform, Sees TROPiCS-02 Results As Not Clinically Meaningful
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $65.00 price target on Gilead Sciences (NASDAQ: GILD) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
